Indolent Lymphoma -  Pipeline Review, H1 2013

Indolent Lymphoma - Pipeline Review, H1 2013

Apr 2013 Global Markets Direct Lymphoma100 Pages Price :
$ 2000

Global Markets Directs, \'Indolent Lymphoma - Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. 

Indolent Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Indolent Lymphoma.
  • A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Indolent Lymphoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Indolent Lymphoma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Indolent Lymphoma 9
Indolent Lymphoma Therapeutics under Development by Companies 11
Indolent Lymphoma Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Indolent Lymphoma Therapeutics - Products under Development by Companies 17
Indolent Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Indolent Lymphoma Therapeutics Development 19
F. Hoffmann-La Roche Ltd. 19
Biogen Idec Inc. 20
Amgen Inc. 21
Sanofi-Aventis 22
Gilead Sciences, Inc. 23
Emergent BioSolutions Inc. 24
Infinity Pharmaceuticals, Inc. 25
Astellas Pharma Inc. 26
Teva Pharmaceutical Industries Limited 27
Cell Therapeutics, Inc. 28
Bayer AG 29
Accentia Biopharmaceuticals, Inc. 30
Mundipharma International Limited 31
Biothera 32
Indolent Lymphoma - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
bendamustine hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
obinutuzumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
pacritinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
SAR-245409 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
BiovaxID - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
TRU-016 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
idelalisib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BAY-80-6946 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ofatumumab + [bendamustine hydrochloride] - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
rituximab - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
IPI-145 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
bendamustine hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ibritumomab tiuxetan + [rituximab] - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
TRU-016 + [bendamustine hydrochloride] + [rituximab] - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PGG beta-glucan - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GS-9973 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
rituximab Biosimilar - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Imprime PGG + [bendamustine hydrochloride] + [rituximab] - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Indolent Lymphoma Therapeutics - Drug Profile Updates 71
Indolent Lymphoma Therapeutics - Discontinued Products 91
Indolent Lymphoma Therapeutics - Dormant Products 92
Indolent Lymphoma - Product Development Milestones 93
Featured News & Press Releases 93
Aug 17, 2011: Emergent Announces Initiation Of Phase Ib/II Study Of TRU-016 In Combination With Rituximab And Bendamustine In Subjects With Relapsed-Indolent Lymphoma 93
Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin\'s Lymphomas At ASH 93
Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies 95
Dec 05, 2010: Calistoga Reports Positive Results From CAL-101 Phase I Trial In Hematologic Malignancies 96
Jun 14, 2010: Calistoga Pharmaceuticals Presents Preclinical And Clinical Data Supporting Benefit Of First In Class, Novel Mechanism Of CAL-101, An Oral Delta Isoform-Selective PI3 Kinase Inhibitor 97

Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100

List of Table


Number of Products Under Development for Indolent Lymphoma, H1 2013 9
Products under Development for Indolent Lymphoma - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Investigation by Universities/Institutes, H1 2013 13
Comparative Analysis by Late Stage Development, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Early Clinical Stage Development, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Investigation by Universities/Institutes, H1 2013 18
F. Hoffmann-La Roche Ltd., H1 2013 19
Biogen Idec Inc., H1 2013 20
Amgen Inc., H1 2013 21
Sanofi-Aventis, H1 2013 22
Gilead Sciences, Inc., H1 2013 23
Emergent BioSolutions Inc., H1 2013 24
Infinity Pharmaceuticals, Inc., H1 2013 25
Astellas Pharma Inc., H1 2013 26
Teva Pharmaceutical Industries Limited, H1 2013 27
Cell Therapeutics, Inc., H1 2013 28
Bayer AG, H1 2013 29
Accentia Biopharmaceuticals, Inc., H1 2013 30
Mundipharma International Limited, H1 2013 31
Assessment by Monotherapy Products, H1 2013 33
Assessment by Combination Products, H1 2013 34
Assessment by Stage and Route of Administration, H1 2013 36
Assessment by Stage and Molecule Type, H1 2013 38
Indolent Lymphoma Therapeutics - Drug Profile Updates 71
Indolent Lymphoma Therapeutics - Discontinued Products 91
Indolent Lymphoma Therapeutics - Dormant Products 92

List of Chart


Number of Products under Development for Indolent Lymphoma, H1 2013 9
Products under Development for Indolent Lymphoma - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 13
Late Stage Products, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Early Clinical Stage Products, H1 2013 16
Assessment by Monotherapy Products, H1 2013 33
Assessment by Combination Products, H1 2013 34
Assessment by Route of Administration, H1 2013 35
Assessment by Stage and Route of Administration, H1 2013 36
Assessment by Molecule Type, H1 2013 37
Assessment by Stage and Molecule Type, H1 2013 38

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top